Jenny has an MA in Experimental Psychology from Oxford University, a PhD in the epidemiology of schizophrenia from the University of Cambridge, and completed post-doctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She joined Cambridge Cognition in 2008 and worked in the clinical trial, healthcare and R&D functions before joining the senior management team in 2014 and becoming CSO in 2016. She has worked on the design and analysis of more than 100 cognitive trials and is the author of 60+ scientific publications and six patents. She has led IP strategy, KOL networking and the scientific validation of medical devices for regulatory approval.
Dr Rebecca Ashfield has 16 years’ experience in the pharmaceutical industry where her work has focused on pre-clinical and clinical development of protein based therapies targeting autoimmune disease and cancer. Dr Ashfield worked for 12 years at Immunocore (formerly Avidex) on the preclinical discovery and clinical development of immuno-oncology therapies. Since leaving Immunocore Dr Ashfield has worked at the University of Oxford’s Jenner Institute on the discovery, manufacture and clinical development of rabies and malaria vaccines. Dr Ashfield’s expertise and experience includes pre-clinical immunology and oncology, protein engineering, GMP manufacture, clinical trials and project leadership of complex multinational collaborations. In addition to her work at the Jenner Institute Dr Ashfield worked as a consultant to Vaccitech Ltd (a recent University of Oxford spin-out) where she helped the leadership team manage GMP vaccine manufacture and complete planning and budgeting work for a large Phase II clinical study. Dr Ashfield obtained her degree and PhD from Oxford University.
With postgraduate qualifications in both business and science, Caroline has a strong commercial, bio-partnering and biologics drug discovery/development background. For over 4 years she has successfully led teams at Wyeth Inc and subsequently Pfizer Inc in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth Inc.
She has been awarded a prestigious Royal Society of Edinburgh commercialisation Fellowship and is a doctoral graduate from the University of Aberdeen in Biochemistry.
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.
Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
Serial entrepreneur with 15 years’ experience in commercialising novel biopharma assets and strategy consulting, having advised teams and led the strategic planning for bringing to market over 50 assets for companies like Pfizer, Allergan, abbVie, Amgen, Shire, Takeda, GSK & Sanofi. Founded the company after losing his mother to Pancreatic Cancer, and seeing a new way to beat cancer by utilising the innate immune system.
Antikor Ltd is a newly established company that is exploiting a novel technology platform called OptiLinked-FDCs, to generate revolutionary products to treat solid cancers. We are a multidisciplinary spin-out from Imperial College London UK now based at the Stevenage Bioscience Catalyst. The Company has over 15 years of pioneering experience in the area of small-format, antibody fragment drug conjugates, and has generated product candidates with optimal pharmacokinetics, pharmacodynamics and other encouraging preclinical data.
Science Creates is a Bristol-based deep tech ecosystem supported and backed by successful entrepreneurs that helps scientists and engineers accelerate their ideas and build disruptive businesses from scientific discoveries. In partnership with the University of Bristol, Science Creates aims to establish Bristol as a global centre for deep tech by providing a combination of specialist incubator facilities (Unit DX and DY), a network of strategic partners and venture capital. The ecosystem aims to provide better healthcare, a cleaner environment, and an improved quality of life for everyone; achieved by supporting scientists to take discoveries off the shelf and into the real world.
Professor Djamgoz is specialised on neuroscience and became Professor of Neurobiology in 1995.
Through biophysics and biomedicine he initiated a new field of cancer research which he calls “neuroscience solutions to cancer” and identified novel voltage-gated sodium channels as anti-metastatic targets.
He was given a second professorship (of Cancer Biology) in 2005. Professor Djamgoz has published more than 200 primary research papers and has edited 6 books / special journal issues. His book “Beat Cancer” was published in 2014.
Sinclair has over 20 years of experience successfully building early-stage life science companies and delivering competitive returns to international investors.
Prior to co-founding Epidarex, Sinclair founded and was Managing Partner of MASA Life Science Ventures, LP (MLSV) an early-stage venture fund that successfully built an international portfolio of leading life science and health technology companies. Sinclair has venture investing experience in the U.S., Europe, East Asia and Canada and has built an international network of blue-chip investors from both the public and private sectors.
He currently serves on the Boards of Directors of Apellis Pharmaceuticals Inc. (NASDAQ: APLS), Clyde Biosciences Ltd., Edinburgh Molecular Imaging Ltd.
Sinclair received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in International Business. He holds an M.A. with Honours in Political Economy from the University of Glasgow and an M.A. in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. Sinclair is a St. Andrew’s Society of New York Scholar. Earlier in his career, he was a political economist with the Center for Strategic and International Studies in Washington, D.C.
He currently serves as the Chairman of Inspiring Scotland, one of the UK’s largest venture philanthropy charities.
After graduating from Oxford in Biochemistry William has over 34 years experience in the Biotech sector with a particular focus on leading SMEs.
Previous companies include R&D Systems, Amersham International, British Biotech and Beckman Coulter alongside small start-ups following outsourcing strategies where relevant.
George Freeman is Minister for Science, Research and Innovation at the Department for Business, Energy & Industrial Strategy.
Elected to Parliament in 2010 after a 15-year career founding high-growth technology companies, George has served in the last three Governments as UK Trade Envoy, the first UK Minister for Life Science, Chair of the No10 Policy Board and Minister of State at the Department for Transport.
Most recently, he led the Prime Minister’s Task Force on Innovation, Growth and Regulatory Reform (TIGRR).
He is Founder of the Big Tent Festival and Foundation, the Reform for Resilience Global Health Commission and the 2020 Conservatives Group. He is also author of Britain Beyond Brexit and the former Chair of the Conservative Policy Forum.
Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer™.
Dr. Vibhor Gupta has a breadth of experience in life sciences through his work in industry and academia over the last two decades. Prior to Pangaea, Vibhor started and built the European business for Quantum Secure, which was an enterprise software solutions provider headquartered in Silicon Valley and was successfully acquired in 2015. Following this, Vibhor served as Senior Vice President of Commercial Strategy and Sales at Seven Bridges Genomics, which was founded at Harvard and provided a cloud based bioinformatics platform. Vibhor has also worked as a management and technology consultant for Deloitte. Vibhor’s academic career focused on conducting molecular biology studies and building AI algorithms with epigenetic, genomic, transcriptomic and clinical trial data in the context of oncology and infectious diseases. Vibhor has access to an extensive global network in the Life sciences industry and is regularly invited to speak at international conferences, government funded programs and investment summits.
Benjamin co-founded Exeliom Biosciences in December 2016. He is an entrepreneur who developed a wide range of competences in various industries such as investment banking (UBS), venture capital (Pacific Channel), pharmaceutical regulatory affairs (Amgen), biotech operations (Theravectys) and even applied research at the Vision Institute in Paris. Benjamin has a Master in Management from ESSEC Business School (Grande Ecole – admission sur concours Prépas) and a master’s degree in Molecular and Cellular Biology from Sorbonne University.
A Life Sciences Investment Update
Tim is Chairman and Managing Partner at Abingworth LLP, a leading global life sciences venture investment firm. Tim joined Abingworth in 2005 having been Chief Executive of Abingworth’s portfolio company, Astex Therapeutics, and was instrumental in establishing it as one of the leading UK biotechnology companies. Tim has held a number of senior management positions in the US and Europe, including CEO of both Datascope Corp. and Thackray Inc, and General Manager at Baxter UK. Tim has a BSc from Exeter University and an MBA from INSEAD. He is a former Director of the BIA and sat on the BVCA Venture Committee and the Wellcome Trust / NHS Health Innovation Challenge Fund. During his time at Abingworth Tim has taken board roles in a number of companies including Adaptate Biotherapeutics, Astex, Fovea, GammaDelta Therapeutics, MEDIAN Technologies, PowderMed, and Sientra.
Peter is a recognized leader in drug discovery, having spent 15 years at Sanofi, most recently as Global Head of External Innovation, Drug Discovery in Business Development. Prior to this, he led global high throughput medicinal chemistry, natural product and antibody drug conjugate departments across Germany, France, and the US, and has contributed to the advancement of many projects into clinical development across several therapeutic areas. He started his career at AstraZeneca leading medicinal chemistry teams in the respiratory and inflammation disease areas. Prior to a postdoctoral position at the University of Pennsylvania, he obtained his PhD from the University of Cambridge, and a BSc in Chemistry from Imperial College London. He holds an MBA from the University of Bath. Over his career in big pharma, he has been involved in hundreds of drug discovery projects, has executed external partnerships and has published numerous papers and patents including co-editing the textbook Small Molecule Medicinal Chemistry: Strategies and Technologies (Wiley).
Simon is a serial entrepreneur whose experience includes technology innovation and investment in Cambridge UK, Boston USA and Wuhan China. Former founder of listed investment company IPSO Ventures PLC.
Enteromics introduces a remote microbiome monitoring platform for sustainable healthcare. Our platform allows users to monitor their personal microbiome through the use of a disposable ingestible device, which is paired to their smartphone through a digital application. The data gathered from the gut microbiome is then transmitted in real-time to provide actionable insights. We provide intelligent and user-friendly analytics that can be used to empower individuals to monitor and manage their health, and to enable our partners to develop effective therapeutics and interventions.
Ed is the Chairman and CEO of Resolution Therapeutics. He is also a Partner at Syncona, and Chairman of OMass Therapeutics. Previously, he was the first CEO and a board member of Autolus Therapeutics. He has also held the role of CEO of Biotica Ltd (Cambridge, UK), President & Chief Business Officer of BrainCells Inc (San Diego, CA), and VP, Business Development & Marketing at Tripos Inc (St Louis, MO). Ed’s early career was spent in research and management positions with Wyeth-Ayerst Inc and British Biotech. He holds a degree and DPhil in Chemistry from the University of Oxford, and is a former Chairman of the BIA, the UK’s trade association for innovative life science companies.
Joe is the CSO and Co-Founder of DJS Antibodies. Joe loves working in a small and focussed team to solve problems creatively. He was a leader in the establishment of HEPTAD, the mAb discovery engine at the heart of DJS, and now oversees all R&D activities within the company. His work covers mAb discovery and screening through to preclinical development of lead drugs, and he works closely with industry-leading experts as well as managing several government funded projects.
Joe holds a BSc in Biochemistry from Imperial College London and a PhD in antibody discovery and characterisation from the University of Oxford. After studying Joe worked as an academic on antibody induction and vaccination.
In his spare time he loves playing the guitar, sailing, kicking a football around and growing vegetables.
Dr Peter Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past ten years, he has created six new companies, targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services.
Dr Jackson has over 25 years’ experience in the sector, previously holding senior executive roles as commercial director then VP of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at predecessor companies Zeneca and ICI.
During 2015-16, Dr Jackson was chairman of the steering committee created to establish the UK’s translational R&D centre focused on antimicrobial resistance, the AMR Centre, and now runs Infex Therapeutics as its executive director.
Peter is founder and Chief Executive Officer of Grey Wolf, setting up the company in 2017 with Tom McCarthy. Peter has over 15 years of experience in biomedical research leading drug discovery projects across disease areas. Prior to Grey Wolf he was at Vertex Pharmaceuticals for 5 and a half years, where he led drug discovery projects and had responsibility for leading a number of target identification teams, and before Vertex he was a post-doc at the MRC. Peter holds a PhD in Biochemistry and Molecular Genetics from the University of Bristol and a BSc in Biochemistry.
At Seventure Partners, we turn innovation into entrepreneurial ventures through financial backing and by sharing the passion of the companies we invest in. Established in 1997, Seventure Partners is one of the European leaders in venture capital, with €850 million net commitments under management as of the end of 2020. We actively fund innovative companies within the two evolving fields of Digital technologies and Life sciences, partnering with those that have strong growth potential.
Hypo-Stream’s M3 burns therapeutic is the result of collaborative work between a group of clinicians, scientists and business people in the UK.
Over ten years ago, founder, Myles Dakin had a hypothesis that auto-regulation of inflammation occurs in humans and mammals at inflammatory foci. The hypothesis sought an endogenous compound and culminated in the testing of M3, which acts as antimicrobial as well as anti-inflammatory.
Early clinical testing within Myles Dakin’s private clinics in London and Cambridge was followed by mechanistic study by Professor Richard Aspinall at Cranfield University Translational Medicine Department.
The team has now expanded to include expertise from drug development and drug commissioning fields as well as drug market access, corporate operational and finance expertise.
M3, analogous to an endogenous product, produces its allosteric modulation of the function of the pro-inflammatory cytokine by modifying its physical structure. Because M3 has a propensity to modify protein structure, it also produces fatal changes to bacterial cytochromes (the energy converter proteins) and has a broad-spectrum antibacterial action. Work with a specialist burns unit produced clinical data exemplifying the life-saving antimicrobial and anti-inflammatory actions.
M3 has immediate applications as a treatment for full thickness burns as well as for use as a wash-therapeutic at time of all surgery. It prevents and treats bacterial colonization and infection and prevents and reduces inflammatory reactions that can often escalate to produce fatal sepsis.
As an allosteric modulator of Iterleukin 6, M3 has potential to impact a large number of inflammatory diseases including, inflammatory skin diseases, inflammatory bowl diseases and potentially respiratory diseases where there is an unmet need.
Dr. Farid Khan, BSc, MSc, PhD(Cantab) Dr. Farid Khan is aremarkable bio-medtech entrepreneur and innovator, who obtained his PhD in protein folding from the University of Cambridgeand previously worked for GlaxoSmithKline in drug discovery.He has developed technologies and therapies for diseases in the developed and the developing world. In 2010, he founded his first biotech, Protein Technologies (http://www.protein-technologies.com)which developed novel biologics, biostimulants from microalgae, and industrial biocatlylsts. In 2012, Dr. Khan founded Pharmakure Ltdwhist he was working at the Manchester Institute of Biotechnology (https://www.mib.manchester.ac.uk/). Pharmakure is a spin out from The University of Manchester(http://www.pharmakure.com)-which has developed drugs for Alzheimer's Disease. More recently, he founded eLucid mHealth Ltd(https://www.elucid-mhealth.com), which measures medication adherence using a Bluetooth electronic pill dispensers-which is being trialed by the NHSand obtained Series A funding from Catapult Ventures. He has recently published on the discovery of new repurposed drugs for malaria and a number of rare diseases such as alkaptonuria (or ‘black bone disease’ which has no current treatment) and Multiple Systems Atrophy(a neurological disease). He has secured £multi-million funds from private and public sources, formed key interdisciplinary collaborations with industry, academic institutions and charities(such as the Welcome Trust) including stakeholders in the UK'shealthcare agenda. A visionary leader and respected scientist, with deep knowledge in the biotechindustry. In 2013Dr.Khan wasawarded an Alumni Achievement Award from the University of Salford, in 2014 in recognition of his work in science and engineering,hewas awarded the Fazlur Rahman Khan award by Muslim News for excellence in engineering/science/technology by Prime Minister David Cameron.Dr. Khan has been interviewed by Bloomberg, The Guardian and the BBC and by a number of peer reviewed journals.In 2019, Dr. Khan formed Chief AI, a company focused on finding repurposed drugs using AI which has received InnovateUK and seed funding. In June, 2019, Dr. Khan was included in the top 100 Asian Starsin UK Tech-a definitive list by Diversity UK in association with KPMG.
Professor La Thangue has over 30 years of experience in biotech entrepreneurship, translational cancer science and drug development. He previously founded Prolifix focused on cell cycle therapeutics, where he acted as CSO and CEO until its merger with TopoTarget which led to a highly successful IPO. He also founded Oxford Cancer Biomarkers, which continues to develop a portfolio of marketed precision cancer medicine tests, where he held senior positions including CEO and CSO. Later on, Nick founded Celleron Therapeutics, a precision medicine company focusing on clinical stage oncology drugs. Argonaut Therapeutics, his most recently founded company, focuses on exploiting the PRMT5-E2F1 signalling pathway in cancer therapy. Nick is Professor of Cancer Biology at Oxford University. He is a Fellow of the Royal Society of Edinburgh, the Academy of Medical Sciences, the European Academy of Cancer Science, the Lister Institute and Professorial Fellow of Linacre College Oxford. He has over 200 publications and is an inventor on numerous patents.
Enhanc3D Genomics is a spinout company from Babraham Institute (Cambridge, UK). It is founded by academic scientists who are leaders in the fields of regulatory genomics and chromosomal architecture.
Per has over 10 years of experience in advising, founding and leading biotech companies developing ground breaking therapies. Per developed and structured the IP and technology portfolio that formed the basis for the founding and £10m Series A financing of Evox and has acted as the company’s Chief Operating Officer since inception. Prior to founding Evox, Per co-founded and served as Chief Executive and Board member of IsletOne Therapeutics, a clinical-stage cell therapy company developing a proprietary mesenchymal stromal cell therapy for the treatment of acute respiratory distress syndrome and autoimmunity. Previously, Per managed a European business development channel for Thomson Reuters IP & Science and before that qualified as a European Patent Attorney in the biotech practice of one of the largest European IP law firms, advising clients on matters ranging from innovation strategy to commercialisation. He started his career as a Research Scientist with Apollo Life Sciences working on nanoparticle drug delivery. Per earned his Ph.D. at the Karolinska Institute, holds an MSc in Biotechnology Engineering, and an MBA from Stockholm University School of Business.
Prior to joining Forbion, Nanna was a Partner at Novo Ventures and a key member of the European deal team focussing on late-stage biopharma investments across Europe. During her 10 years at Novo, Nanna was involved in numerous successful European growth stage investments including high-profile cross-over deals and IPOs. Notable investments led by Nanna include NBE Therapeutics GmbH, which was later acquired by Boehringer Ingelheim, LAVA Therapeutics N.V. (NASDAQ: LVTX) Orphazyme A/S (ORPHA.CO; ORPH), Inventiva S.A. (NASDAQ: IVA – Euronext Paris: IVA), ObsEva SA (NASDAQ: OBSV; SIX: OBSN), Numab Therapeutics AG, Nodthera Limited and ReViral Ltd.
Argonaute RNA Ltd. is developing safe and reliable methods of temporarily silencing target genes in different tissue cells.
Dr James McIlroy is a qualified medical doctor and biopharmaceutical entrepreneur that is widely recognised as a pioneer and thought leader in the application of the microbiome to treat disease.
James Founded EnteroBiotix with the vision of building one of the world’s leading microbiome drug development companies. As CEO, James combines his medical, business and scientific expertise to effectively lead the Company’s drug development programmes.
James holds a BMedSci (Hons) from the University of Edinburgh and an MBChB (with distinction) from the University of Aberdeen.
James is a named inventor on several microbiome related patent applications and has been published as first author in journals such as Alimentary Pharmacology & Therapeutics, Frontline Gastroenterology and Clinical Immunology.
Start Codon focuses on supporting highly disruptive, translational innovations created by exceptional teams from across the globe.
Dr Jim Millen has over 15 years’ experience in pharmaceuticals and biotechnology gained at a number of blue chip global companies as well as smaller UK-based organisations.
At Allergan, Jim was responsible for corporate development in its Europe, Africa and Middle East region where he was pivotal in expanding the company’s geographical footprint before moving to a senior role responsible for commercial strategy and market access. Prior to that, at GSK, Jim held business development roles of increasing responsibility including within the company’s innovative Centre of Excellence for External Drug Discovery. In the last 18 months Jim has supported a number of smaller companies in fund raising and strategic partnering activities. Over the course of his career he has completed an array of deals worth many hundreds of millions of dollars, spanning licencing, acquisition, divestment, development and commercialisation.
Jim studied medicine at Queens’ College, Cambridge University and qualified as a doctor from the London Medical School. He holds an MBA from INSEAD.
Dr. Jon Moore is CEO and is also an Operating Partner at Advent Life Sciences. Jon has >25 years of experience in Life Sciences starting with postdoctoral work in molecular motors & cell cycle control including a period with Nobel Prize winner Tim Hunt, followed by 10 years small molecule drug discovery experience at Vernalis. More recently Jon was CSO of Horizon Discovery where he helped established the companies world-leading capabilities for using CRISPR/Cas9 in target ID and validation and co-founded Avvinity Therapeutics. Jon holds a Ph.D. from the University of Newcastle upon Tyne and was published >40 peer-reviewed papers.
Neurologist with a background in biomedical entrepreneurship. Studied neuroscience at Cambridge and clinical medicine at Oxford. Graduated top of his year and was the first medical student in Oxford history to be awarded merits in every exam. Top ranking applicant to London academic medical training and was the highest scoring applicant to neurology specialist training in the UK. Awarded a Kennedy Scholarship to complete a Master's degree at Harvard University, studying entrepreneurship, negotiation and communication. He won the MIT $100K Accelerate Entrepreneurship Competition in Boston by inventing a neurological device and creating an award-winning business-plan. He also founded an internationally recognised teaching platform for medical students in war-zones.
Dr Obolensky is a microbiologist and immunologist with experience in pharmaceuticals, research institutions and private equity. She has extensive experience in intellectual property management, commercialisation, and research.
She started her career at Porton International, which commercialised drugs and vaccines originating from the British government’s Centre for Applied Microbiology and Research at Porton Down. Dr Obolensky established the company’s Hong Kong office to oversee clinical development and trials in Asia for novel products.
Following her work at Porton, Dr Obolensky completed a PhD in immunology. She then worked as an independent consultant advising companies and institutions on ways to evaluate, protect, and maximise their IP for commercialisation.
Later, Dr Obolensky served as Head of External Sciences for H2O Venture Partners, a private equity firm focused on early stage technologies. Since 2011, Dr Obolensky has worked as a consultant for the British Heart Foundation responsible for auditing BHF-funded scientists across 14 British universities.
Dr. Obolensky holds a PhD from Keble College, University of Oxford. She is a Fellow of the Royal Society of Medicine and a Member of British Society of Immunology.
Manish has a doctorate in mathematical modelling with an emphasis on dealing with large, complex datasets. He is the technical architect of Jiva.ai, a new machine learning algorithm that will form the basis of a new breed of AIs.
Katy is a tax director in BDO's Innovation & Technology Group and has specialised in R&D tax relief and patent box claims for over 10 years. She understands the importance of maximising cash refunds/savings from these reliefs and ensuring timely repayments from HMRC and uses her experience and HMRC relationships to enable our clients to achieve this.
Jon is CEO of MitoRx Therapeutics. Prior experience biopharma advisory consultancy at Jon Rees Associates Ltd, 15 years in industry and vast network. Experience includes rare disease business development for Takeda Pharma, venture capital sourcing for LSP, advising biotechs on fundraising: Ducentis BioTherapeutics and others. Experience includes a decade as spin-out CEO building OBN/BioTrinity.
LoQus23 is a DDF-formed company focusing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat neurodegenerative diseases.
Mike Romanos is a co-founder and Chief Executive of Microbiotica. He has 30 years’ experience in the biotech and pharma industry and previously co-founded Crescendo Biologics which he built and led as CEO and CSO, developing a leading antibody fragment discovery platform and pipeline in oncology and inflammation. Prior to that he held global VP roles in GlaxoSmithKline R&D over 10 years, during which time he formed and led major transnational divisions which helped shape the company’s discovery platforms and pipelines across therapeutic areas and modalities. In his last role he led a trans-national group of 300 staff providing genomics, target and biomarker discovery, and platform biology for R&D.
Mike is highly experienced in the biotech translation and commercialisation, currently serving as a Non-Exec Director of the life-sciences charity LifeArc, and previously as Translational Adviser in Biomedicine at Imperial College, Venture Partner to UK Innovation and Science Seed Fund, and committee member on the MRC’s Developmental Pathway Funding Scheme for translational academic research.
Mike’s academic work included research in influenza virology (MRC, National Institute for Medical Research) and in yeast genetics and biotechnology (University of Leicester). He holds a degree in Natural Sciences from Cambridge University, a PhD in Molecular Virology from Imperial College, and is a Fellow of the Royal Society of Biology.
Dr Jack Scannell has unusually broad experience relevant to Unify; in drug discovery, in biopharma investment, in R&D productivity, and in neuroscience. He led Discovery Biology at E-Therapeutics PLC, an Oxford-based biotech firm. He was Co-Head of European Pharmaceuticals and Biotech at UBS Investment Bank and Head of European Healthcare at Sanford Bernstein.
He has a PhD in Neuroscience from Oxford University and a Bachelor’s degree in Medical Sciences from Cambridge University. He is perhaps best known for his work on biopharma R&D productivity.
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics).
Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally.
We are pushing the frontiers to explore the intersection between immunology and machine learning.
Paul Thompson is Operations Director for Matoke® Holdings and is accountable for formulation development and production. He has a background in aerospace engineering and has extensive experience of the design and delivery of information systems. He has worked with other technology start-ups and universities, helping to commercialise innovative technologies.
Pneumagen is developing a glycan targeted intranasally delivered therapy for the pan-viral, universal treatment of infectious diseases of the respiratory tract
Antiverse is a new type of antibody discovery company accelerating drug development. The Antiverse platform exists at the intersection of structural biology, machine learning and medicine to enable breakthroughs to happen more quickly and cost-effectively. Recognized as one of the top biotech startups in the UK, their service is already in use by big pharma. Founded in 2017, Antiverse is dedicated to engineering the future of drug development to change the course of people's lives. The company is headquartered in Cardiff, Wales.
Dr Clare Wareing PhD, Founder and CEO (Director). Senior executive and entrepreneur with the vision, drive and experience of successful oncology drug development and company exits to lead the company forward.
Tim’s career in the life sciences has encompassed start-ups, venture capital, investment banking and equity research. He has held senior positions at a number of firms including NM Rothschild, Hambrecht and Quist, UBS, SG Cowen and Pacific Growth Equities. In 2013 he founded Longcross Advisers, a life science-focused corporate finance firm. He gained his PhD from the MRC’s Laboratory of Molecular Biology in Cambridge and a BSc (Hons) in biochemistry from Imperial College, London.
Will studied Natural Sciences at Bath University and began his career as a management consultant for Accenture. He worked with a very wide variety of clients including Deutsche Bank, BBC, Thales, and BT, his roles were across strategy, estimation, planning and delivery. More recently he was CEO of a direct to consumer business, The London Sock Company, before joining Guy in the medical world. He brings planning and delivery rigor as well as strong business strategy and management skills.
Bart is an accomplished biotech CEO with over 30 years’ experience in innovative drug development, biotech financing, business development and licensing. He has extensive experience in working with research and development based companies in pharmaceutical product development in several therapeutic areas, including cancer, fibrosis and cardiovascular diseases. Bart Wuurman has previously executed successful biotech company exits in the UK and in the Netherlands. He was responsible for pharma licensing deals worth over $700 million. Bart was CEO of De Novo pharmaceuticals (UK), AM-Pharma, Lanthio Pharma and is Director of Lyramid (Australia) and Hercules Pharmaceuticals. Before joining Apaxen, Bart was also Managing Director of DDF Ventures, a life-science focused venture fund with a portfolio of start-up companies in The Netherlands.